CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Charles Wagner

Executive Vice President, Chief Operating Officer & Chief Financial Officer, Vertex Pharmaceuticals

Search every verified Charles Wagner interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Charles Wagner, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Vertex Pharmaceuticals, discussed the company's second quarter 2026 financial results during an earnings call on August 3, 2026. He reported total revenue of $3.3 billion, a 12% increase year-over-year, with growth balanced between US and international markets, and noted an approximate 170 basis point benefit from foreign exchange rates. Wagner stated that global cystic fibrosis (CF) revenue grew 11% year-over-year, and highlighted contributions from new disease areas, including Casgevy, which delivered $76 million. He also reported non-GAAP earnings per share of $4.73, representing 5% growth versus the prior year, and noted the company ended the quarter with approximately $13.6 billion in cash and investments, having deployed about $455 million to repurchase roughly 1 million shares. Wagner also addressed the company's capital deployment priorities, stating that investing in innovation remains the top priority, as evidenced by the announced acquisition of Cinetics for approximately $8.8 billion net of cash acquired. He announced that Vertex was raising its full-year 2026 total revenue guidance to a range of $13.1 to $13.2 billion, citing strong first-half performance and business momentum. The guidance reflects continued strong performance from the CF franchise, including Ultomiris, as well as growing year-over-year contributions from Casgevy and other products. Wagner reiterated expectations for revenue of $500 million or greater from non-CF products and included an anticipated 150 basis point impact in the outlook.

Recent appearances

  • Vertex Pharmaceuticals Q2 FY26 Earnings Call | $VRTX | 🔴 WATCH LIVE

    August 03, 2026 · 📺 Benzinga

    Vertex Pharmaceuticals Inc (VRTX) — Q2 FY26 Earnings Call Live coverage with Benzinga. Q2 FY26 Results EPS: $4.73 (est. $4.63) — inline Revenue: $3.33B (est. $3.21B) — inline Reported: 2026-08-03 Recent Quarters Q1 FY26 (2026-05-04): EPS $4.47 vs est $4.18 · Rev $2.99B vs est $2.99B Q4 FY25 (2026-02-12): EPS $5.03 vs est $4.85 · Rev $3.19B vs est $3.17B Q3 FY25 (2025-11-03): EPS $4.80 vs est $4.35 · Rev $3.08B vs est $3.05B Q2 FY25 (2025-08-04): EPS $4.52 vs est $4.05 · Rev $2.96B vs est $2.90B About Vertex Pharmaceuticals Inc Vertex Pharmaceuticals is a global biotechnology company that d…

    Watch on YouTube ↗

  • Vertex Pharmaceuticals Q1 FY26 Earnings Call | $VRTX | 🔴 WATCH LIVE

    May 04, 2026 · 📺 Benzinga

    Vertex Pharmaceuticals Inc (VRTX) — Q1 FY26 Earnings Call Live coverage with Benzinga. Q1 FY26 Results EPS: $4.47 (est. $4.18) — inline Revenue: $2.99B (est. $2.99B) — inline Reported: 2026-05-04 Recent Quarters Q4 FY25 (2026-02-12): EPS $5.03 vs est $4.85 · Rev $3.19B vs est $3.17B Q3 FY25 (2025-11-03): EPS $4.80 vs est $4.35 · Rev $3.08B vs est $3.05B Q2 FY25 (2025-08-04): EPS $4.52 vs est $4.05 · Rev $2.96B vs est $2.90B Q1 FY25 (2025-05-05): EPS $4.06 vs est $4.29 · Rev $2.77B vs est $2.86B About Vertex Pharmaceuticals Inc Vertex Pharmaceuticals is a global biotechnology company that d…

    Watch on YouTube ↗

  • $VRTX Vertex Pharmaceuticals Q1 2025 Earnings Conference Call

    May 05, 2025 · 📺 EARNMOAR

    05/05/2025 Q&A: 32:13 Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY f…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →